Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2016 - 2025)

Enanta Pharmaceuticals' Other Non-Current Assets history spans 14 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 3474.47% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, up 3474.47%, while the annual FY2025 figure was $3.4 million, 0.0% changed from the prior year.
  • Other Non-Current Assets reached $3.4 million in Q4 2025 per ENTA's latest filing, roughly flat from $3.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.0 million in Q2 2022 to a low of $92000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.9 million, with a median of $733000.0 recorded in 2022.
  • The largest YoY upside for Other Non-Current Assets was 3474.47% in 2025 against a maximum downside of 97.2% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $608000.0 in 2021, then increased by 15.3% to $701000.0 in 2022, then rose by 9.13% to $765000.0 in 2023, then tumbled by 87.71% to $94000.0 in 2024, then skyrocketed by 3474.47% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Other Non-Current Assets are $3.4 million (Q4 2025), $3.4 million (Q3 2025), and $94000.0 (Q2 2025).